These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 27651240

  • 21. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
    Maze MJ, Paynter J, Chiu W, Hu R, Nisbet M, Lewis C.
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):955-60. PubMed ID: 27287650
    [Abstract] [Full Text] [Related]

  • 22. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
    Wang HF, Wang R, O'Gorman M, Crownover P, Naqvi A, Jafri I.
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1596-601. PubMed ID: 24200275
    [Abstract] [Full Text] [Related]

  • 23. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.
    Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW.
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2670-9. PubMed ID: 9420037
    [Abstract] [Full Text] [Related]

  • 24. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J.
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP, Medellín-Garibay SE, Salazar-González RA, Ortiz-Álvarez A, Magaña-Aquino M, Rodríguez-Pinal CJ, Portales-Pérez DP, Romano-Moreno S, Milán-Segovia RDC.
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
    Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA.
    Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
    [Abstract] [Full Text] [Related]

  • 33. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, Goldberg SV, Tuberculosis Trials Consortium.
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [Abstract] [Full Text] [Related]

  • 34. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK, Günther G, Kibuule D, Hunter C, Rennie TW.
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [Abstract] [Full Text] [Related]

  • 35. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2002 Feb 21; 233(1-2):169-77. PubMed ID: 11897421
    [Abstract] [Full Text] [Related]

  • 36. Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.
    Mah A, Kharrat H, Ahmed R, Gao Z, Der E, Hansen E, Long R, Kunimoto D, Cooper R.
    Int J Tuberc Lung Dis; 2015 Feb 21; 19(2):210-5. PubMed ID: 25574921
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.
    Ahmad Z, Pandey R, Sharma S, Khuller GK.
    Int J Antimicrob Agents; 2006 May 21; 27(5):409-16. PubMed ID: 16624533
    [Abstract] [Full Text] [Related]

  • 38. A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs.
    Cevik M, Sturdy A, Maraolo AE, Dekkers BGJ, Akkerman OW, Gillespie SH, Alffenaar JWC.
    Int J Tuberc Lung Dis; 2024 Sep 01; 28(9):454-460. PubMed ID: 39188008
    [Abstract] [Full Text] [Related]

  • 39. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide.
    Walubo A, Chan K, Woo J, Chan HS, Wong CL.
    Methods Find Exp Clin Pharmacol; 1991 Oct 01; 13(8):551-6. PubMed ID: 1956210
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.